<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03333681</url>
  </required_header>
  <id_info>
    <org_study_id>931523</org_study_id>
    <secondary_id>122</secondary_id>
    <nct_id>NCT03333681</nct_id>
  </id_info>
  <brief_title>Evaluation of Stem Cell Therapy Effects on the Immune Response in Rheumatoid Arthritis Patients</brief_title>
  <official_title>Evaluation of Mesenchymal Stem Cell Therapy Effects on the Cellular and Humoral Immune Responses and Additionally Study on the Effect of Chemokines in Homing of the Immune Cells in Refractory Rheumatoid Arthritis Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mashhad University of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mashhad University of Medical Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      1. Objectives: Evaluation of mesenchymal stem cell therapy effects on cellular and humoral&#xD;
           immune responses in refractory rheumatoid arthritis (RA) patients.&#xD;
&#xD;
        2. Design: This study has been performed as a phase 1 clinical trial.&#xD;
&#xD;
        3. Setting and conduct: Autologous bone marrow derived mesenchymal stem cells were obtained&#xD;
           by bone marrow aspiration and cultured in Minimum Essential Medium-Alpha (MEM-alpha) for&#xD;
           4 weeks in standard clean room and then transfused to RA patients intravenously.&#xD;
&#xD;
        4. Participant's major eligibility criteria is as follows: Ten refractory rheumatoid&#xD;
           arthritis patients who show resistance to non biological Disease-modifying antirheumatic&#xD;
           drugs (DMARDs) after 6 to 12 months have been enrolled in this study.&#xD;
&#xD;
        5. Intervention: A single dose of intravenous autologous bone marrow derived mesenchymal&#xD;
           stem cells have been administered into patients with resistance to non-biological&#xD;
           DMARDs.&#xD;
&#xD;
        6. Main outcome measures (variables): Finding of mesenchymal stem cell therapy effects on&#xD;
           the cellular and humoral immune responses and evaluation of the effect of chemokines in&#xD;
           homing of immune cells following the intervention.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Refractory rheumatoid arthritis patients who met the inclusion/exclusion criteria have been&#xD;
      selected. After signing informed consent form, autologous stem cells were obtained by bone&#xD;
      marrow aspiration. Isolation and culture (3 to 4 weeks in MEM-alpha medium) of mesenchymal&#xD;
      stem cells (MSCs) were performed in accredited good manufacturing practices (GMP) clean room.&#xD;
      A panel of cluster of differentiation (CD) markers including CD105, CD166, CD44, CD45, CD90,&#xD;
      and CD34 were checked for making sure about differentiation of cells into MSCs after 3-4&#xD;
      weeks of cell culture. Viability of MSCs was checked by Trypan blue testing and all of the&#xD;
      cultivations were negative for bacterial contamination. A single dose of 1000000 to 2000000&#xD;
      mesenchymal stem cells/kg infused into patients intravenously. To prevent anaphylactic&#xD;
      reactions, a single intravenous dose of hydrocortison (100 ml) and oral dimenhydrinate (10&#xD;
      ml) were administered before MSCs infusion into patients. The effects of mesenchymal stem&#xD;
      cells on the cellular and humoral immune responses and also the role of chemokines in homing&#xD;
      of immune cells were studied at time points 1, 6 and 12 months after intravenous&#xD;
      administration of MSCs in refractory rheumatoid arthritis.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 20, 2016</start_date>
  <completion_date type="Actual">September 15, 2018</completion_date>
  <primary_completion_date type="Actual">August 15, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Effect of mesenchymal stem cells therapy on the percentage of regulatory T cells</measure>
    <time_frame>At 0 and 6 months follow up</time_frame>
    <description>Percentage change in regulatory T cells from baseline which is analysed by fluorescence-activated cell sorting (FACS)</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>Refractory rheumatoid arthritis patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Autologous mesenchymal stem cells</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Autologous mesenchymal stem cells</intervention_name>
    <description>A single intravenous administration of autologous bone marrow derived mesenchymal stem cells(1000000 to 2000000 cells/Kg)</description>
    <arm_group_label>Refractory rheumatoid arthritis patients</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Resistant RA patients to non-biological DMARDs;&#xD;
&#xD;
          -  Treated RA patients by non-biological drugs;&#xD;
&#xD;
          -  Treated RA patients by Prednisolone, Hydroxychloroquine, Sulfasalazine and&#xD;
             Methotrexate;&#xD;
&#xD;
          -  Patients age between 35-60 years;&#xD;
&#xD;
          -  Refractory RA patients with no other rheumatologic disorders and inflammatory&#xD;
             diseases.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Non-resistant RA patients to non-biological DMARDs.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mojgan Mohammadi, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mashhad University of Medical Sciences</affiliation>
  </overall_official>
  <reference>
    <citation>Álvaro-Gracia JM, Jover JA, García-Vicuña R, Carreño L, Alonso A, Marsal S, Blanco F, Martínez-Taboada VM, Taylor P, Martín-Martín C, DelaRosa O, Tagarro I, Díaz-González F. Intravenous administration of expanded allogeneic adipose-derived mesenchymal stem cells in refractory rheumatoid arthritis (Cx611): results of a multicentre, dose escalation, randomised, single-blind, placebo-controlled phase Ib/IIa clinical trial. Ann Rheum Dis. 2017 Jan;76(1):196-202. doi: 10.1136/annrheumdis-2015-208918. Epub 2016 Jun 7.</citation>
    <PMID>27269294</PMID>
  </reference>
  <reference>
    <citation>Liang J, Li X, Zhang H, Wang D, Feng X, Wang H, Hua B, Liu B, Sun L. Allogeneic mesenchymal stem cells transplantation in patients with refractory RA. Clin Rheumatol. 2012 Jan;31(1):157-61. doi: 10.1007/s10067-011-1816-0. Epub 2011 Aug 12.</citation>
    <PMID>21837432</PMID>
  </reference>
  <reference>
    <citation>Wang L, Wang L, Cong X, Liu G, Zhou J, Bai B, Li Y, Bai W, Li M, Ji H, Zhu D, Wu M, Liu Y. Human umbilical cord mesenchymal stem cell therapy for patients with active rheumatoid arthritis: safety and efficacy. Stem Cells Dev. 2013 Dec 15;22(24):3192-202. doi: 10.1089/scd.2013.0023. Epub 2013 Oct 4.</citation>
    <PMID>23941289</PMID>
  </reference>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>September 14, 2017</study_first_submitted>
  <study_first_submitted_qc>November 3, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 7, 2017</study_first_posted>
  <last_update_submitted>March 12, 2019</last_update_submitted>
  <last_update_submitted_qc>March 12, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 13, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mashhad University of Medical Sciences</investigator_affiliation>
    <investigator_full_name>Dr. Mojgan Mohammadi</investigator_full_name>
    <investigator_title>Associate professor</investigator_title>
  </responsible_party>
  <keyword>Rheumatoid arthritis</keyword>
  <keyword>Stem Cells</keyword>
  <keyword>Cellular immunity</keyword>
  <keyword>Humoral immunity</keyword>
  <keyword>chemokines</keyword>
  <keyword>homing of immune cells</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

